Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders

Clinical trial NCT06672705 · RECRUITING

Trial details

NCT number: NCT06672705
Sponsor: Timothy Voorhees
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder EBV-Related Post-Transplant Lymphoproliferative Disorder Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder

Start date: 2025-06-16
Primary completion: 2026-12-31
Enrollment: 26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.